SOAT1 and myeloproliferative neoplasm: Therefore, at least some of the initial dependency on JAK2V617F may be lost during MPN pathogenesis, and JAK inhibition may only be able to tackle those aspects of the diseases that continue to rely on constitutive activation of the JAK/STAT pathway.